NeuroPhage Pharmaceuticals Closes $12.4M Series B Round NeuroPhage Pharmaceuticals, Inc. (NeuroPhage), a privately held biotechnology company developing a protein disaggregation platform for treatment of neurodegenerative diseases, announced that it has secured $12.4 million in Series B financing, which will be mostly directed to the IND-enabling activities in preparation of a Phase 1 clinical trial for NPT001, NeuroPhage’s lead product candidate for the treatment of Alzheimer’s disease, and include further work to expand the platform. [Neurophage Pharmaceuticals, Inc. Press Release] Zalicus Publishes Data on Sodium Channel Compound in Pain Models Zalicus Inc. announced the publication of preclinical data in the journal PAIN. The paper describes the activity of Z212, a novel proprietary small organic compound that acts to modulate Nav1.7 and Nav1.8 sodium channels and to reduce neuropathic pain by targeting the hyper-excitability associated with chronic pain signaling pathways. [Zalicus Inc. Press Release]
BrainStorm Cell Therapeutics Raises $3.6 Million from Institutional and Private Investors in Equity Financing BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, announced that it has entered into securities purchase agreements with certain institutional and other investors in connection with a private placement financing in reliance upon Regulation S. [BrainStorm Cell Therapeutics Inc. Press Release]
Neuralstem Announces First Subject Dosed in NSI-189 Safety Testing Toward Major Depressive Disorder Trial Neuralstem, Inc. announced that the first subject was dosed in a Phase Ia trial to evaluate the safety of its drug, NSI-189, which is being developed for the treatment of major depressive disorder and other psychiatric indications. [Neuralstem, Inc. Press Release]
Stem Cell Facility Expands Campus’ Research Capabilities The University of California, Merced, celebrates the opening of its state-of-the-art Stem Cell Instrumentation Foundry, made possible through the support of the California Institute for Regenerative Medicine (CIRM) and Ed and Jeanne Kashian of Fresno. [University of California, Merced Press Release]
Lilly’s Neuroscience Research Chief Resigns The head of Eli Lilly’s research into Alzheimer’s disease, schizophrenia and other neurological diseases is unexpectedly leaving the company. [The Wall Street Journal] |